Unity Biotechnology Analyst Ratings
Unity Biotechnology Analyst Ratings
While ratings are subjective and will change, the latest Unity Biotechnology (UBX) rating was a upgraded with a price target of $0.00 to $0.00. The current price Unity Biotechnology (UBX) is trading at is $1.94, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/16/2023 | — | Wedbush | Upgrades | Neutral → Outperform | |
| 11/14/2023 | 415.46% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 08/09/2023 | 415.46% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 06/26/2023 | 3.09% | Wedbush | $3 → $2 | Downgrades | Outperform → Neutral |
| 05/31/2023 | 415.46% | Roth MKM | → $10 | Initiates Coverage On | → Buy |
| 05/26/2023 | 209.28% | Citigroup | $5 → $6 | Maintains | Buy |
| 05/10/2023 | 415.46% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 04/25/2023 | 54.64% | Wedbush | $5 → $3 | Maintains | Outperform |
| 03/28/2023 | 209.28% | Mizuho | $12 → $6 | Maintains | Buy |
| 03/28/2023 | 157.73% | Wedbush | $35 → $5 | Maintains | Outperform |
| 03/28/2023 | 415.46% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 03/28/2023 | 157.73% | Citigroup | $15 → $5 | Maintains | Buy |
| 03/16/2023 | 1704.12% | Wedbush | → $35 | Reiterates | → Outperform |
| 03/16/2023 | 415.46% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 02/15/2023 | 415.46% | HC Wainwright & Co. | → $10 | Maintains | Buy |
| 11/16/2022 | 518.56% | Mizuho | $80 → $12 | Maintains | Buy |
| 11/09/2022 | 415.46% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 11/02/2022 | 1755.67% | Wedbush | $4 → $36 | Maintains | Outperform |
| 08/16/2022 | 312.37% | Mizuho | $7 → $8 | Maintains | Buy |
| 08/15/2022 | 312.37% | Citigroup | $5 → $8 | Maintains | Buy |
| 05/17/2022 | 157.73% | Citigroup | $6 → $5 | Maintains | Buy |
| 01/04/2022 | 106.19% | Roth Capital | → $4 | Upgrades | Neutral → Buy |
| 11/10/2021 | 260.82% | Mizuho | $5 → $7 | Upgrades | Neutral → Buy |
| 06/28/2021 | — | Citigroup | Upgrades | Sell → Buy | |
| 06/07/2021 | 518.56% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 08/18/2020 | 157.73% | Morgan Stanley | → $5 | Downgrades | Overweight → Equal-Weight |
| 08/18/2020 | — | Mizuho | Downgrades | Buy → Neutral | |
| 08/18/2020 | 157.73% | Citigroup | $31 → $5 | Downgrades | Buy → Neutral |
| 08/17/2020 | 106.19% | Roth Capital | $35 → $4 | Downgrades | Buy → Neutral |
| 07/28/2020 | 1704.12% | Roth Capital | → $35 | Initiates Coverage On | → Buy |
| 04/15/2020 | 570.1% | Morgan Stanley | $14 → $13 | Maintains | Overweight |
| 12/12/2019 | 930.93% | Cantor Fitzgerald | → $20 | Assumes | → Overweight |
| 03/07/2019 | 982.47% | Cantor Fitzgerald | → $21 | Initiates Coverage On | → Overweight |
| 12/19/2018 | 1137.11% | Morgan Stanley | $25 → $24 | Maintains | Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/16/2023 | — | Wedbush | 升級 | 中性 → 跑贏大盤 | |
| 11/14/2023 | 415.46% | HC Wainwright & Co. | → 10 美元 | 重申 | 購買 → 購買 |
| 08/09/2023 | 415.46% | HC Wainwright & Co. | → 10 美元 | 重申 | 購買 → 購買 |
| 06/26/2023 | 3.09% | Wedbush | 3 美元 → 2 美元 | 降級 | 跑贏大盤 → 中性 |
| 05/31/2023 | 415.46% | Roth MKM | → 10 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/26/2023 | 209.28% | 花旗集團 | 5 美元 → 6 美元 | 維護 | 買 |
| 05/10/2023 | 415.46% | HC Wainwright & Co. | → 10 美元 | 重申 | → 購買 |
| 2023 年 4 月 25 日 | 54.64% | Wedbush | 5 美元 → 3 美元 | 維護 | 跑贏大盤 |
| 03/28/2023 | 209.28% | 瑞穗市 | 12 美元 → 6 美元 | 維護 | 買 |
| 03/28/2023 | 157.73% | Wedbush | 35 美元 → 5 美元 | 維護 | 跑贏大盤 |
| 03/28/2023 | 415.46% | HC Wainwright & Co. | → 10 美元 | 重申 | → 購買 |
| 03/28/2023 | 157.73% | 花旗集團 | 15 美元 → 5 美元 | 維護 | 買 |
| 03/16/2023 | 1704.12% | Wedbush | → 35 美元 | 重申 | → 跑贏大盤 |
| 03/16/2023 | 415.46% | HC Wainwright & Co. | → 10 美元 | 重申 | → 購買 |
| 02/15/2023 | 415.46% | HC Wainwright & Co. | → 10 美元 | 維護 | 買 |
| 11/16/2022 | 518.56% | 瑞穗市 | 80 美元 → 12 美元 | 維護 | 買 |
| 11/09/2022 | 415.46% | HC Wainwright & Co. | 12 美元 → 10 美元 | 維護 | 買 |
| 11/02/2022 | 1755.67% | Wedbush | 4 美元 → 36 美元 | 維護 | 跑贏大盤 |
| 08/16/2022 | 312.37% | 瑞穗市 | 7 美元 → 8 美元 | 維護 | 買 |
| 08/15/2022 | 312.37% | 花旗集團 | 5 美元 → 8 美元 | 維護 | 買 |
| 05/17/2022 | 157.73% | 花旗集團 | 6 美元 → 5 美元 | 維護 | 買 |
| 2022 年 4 月 1 日 | 106.19% | 羅斯資本 | → 4 美元 | 升級 | 中性 → 買入 |
| 11/10/2021 | 260.82% | 瑞穗市 | 5 美元 → 7 美元 | 升級 | 中性 → 買入 |
| 2021 年 6 月 28 日 | — | 花旗集團 | 升級 | 賣出 → 買入 | |
| 06/07/2021 | 518.56% | HC Wainwright & Co. | → 12 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/18/2020 | 157.73% | 摩根士丹利 | → 5 美元 | 降級 | 超重 → 重量相等 |
| 08/18/2020 | — | 瑞穗市 | 降級 | 買入 → 中性 | |
| 08/18/2020 | 157.73% | 花旗集團 | 31 美元 → 5 美元 | 降級 | 買入 → 中性 |
| 2020 年 8 月 17 日 | 106.19% | 羅斯資本 | 35 美元 → 4 美元 | 降級 | 買入 → 中性 |
| 2020 年 7 月 28 日 | 1704.12% | 羅斯資本 | → 35 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 4 月 15 日 | 570.1% | 摩根士丹利 | 14 美元 → 13 美元 | 維護 | 超重 |
| 2019 年 12 月 12 日 | 930.93% | 坎託·菲茨傑拉德 | → 20 美元 | 假設 | → 超重 |
| 2019 年 7 月 3 日 | 982.47% | 坎託·菲茨傑拉德 | → 21 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 12/19/2018 | 1137.11% | 摩根士丹利 | 25 美元 → 24 美元 | 維護 | 超重 |
What is the target price for Unity Biotechnology (UBX)?
Unity Biotechnology (UBX) 的目標價格是多少？
The latest price target for Unity Biotechnology (NASDAQ: UBX) was reported by Wedbush on November 16, 2023. The analyst firm set a price target for $0.00 expecting UBX to fall to within 12 months (a possible -100.00% downside). 15 analyst firms have reported ratings in the last year.
Wedbush於2023年11月16日公佈了Unity Biotechnology（納斯達克股票代碼：UBX）的最新目標股價。該分析公司將目標股價定爲0.00美元，預計UBX將在12個月內跌至12個月內（可能下跌-100.00％）。去年有15家分析公司公佈了評級。
What is the most recent analyst rating for Unity Biotechnology (UBX)?
分析師對Unity Biotechnology（UBX）的最新評級是多少？
The latest analyst rating for Unity Biotechnology (NASDAQ: UBX) was provided by Wedbush, and Unity Biotechnology upgraded their outperform rating.
Wedbush對Unity Biotechnology（納斯達克股票代碼：UBX）的最新分析師評級由Wedbush提供，Unity Biotechnolog
When is the next analyst rating going to be posted or updated for Unity Biotechnology (UBX)?
Unity Biotechnology（UBX）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Unity Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Unity Biotechnology was filed on November 16, 2023 so you should expect the next rating to be made available sometime around November 16, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Unity Biotechnology的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Unity Biotechnology的最後一次評級是在2023年11月16日發佈的，因此您應該預計下一個評級將在2024年11月16日左右公佈。
Is the Analyst Rating Unity Biotechnology (UBX) correct?
分析師對Unity生物技術（UBX）的評級是否正確？
While ratings are subjective and will change, the latest Unity Biotechnology (UBX) rating was a upgraded with a price target of $0.00 to $0.00. The current price Unity Biotechnology (UBX) is trading at is $1.94, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Unity Biotechnology（UBX）評級已上調，目標股價爲0.00美元至0.00美元。Unity Biotechnology（UBX）目前的交易價格爲1.94美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。
